Results 141 to 150 of about 48,441 (262)

Can Hormonal Therapy Improve the Outcomes of mTESE in Patients With Non‐Obstructive Azoospermia?

open access: yesAndrology, Volume 14, Issue 6, Page 1859-1872, September 2026.
ABSTRACT Background Non‐obstructive azoospermia (NOA) represents the most severe form of male infertility. Hypogonadism is common in NOA patients, and normal testosterone (T) levels are considered essential for spermatogenesis. Fertility‐preserving hormonal therapy (FpHT) has been proposed to optimize hormonal milieu and improve sperm retrieval rates ...
Mattia Anfosso   +5 more
wiley   +1 more source

Evaluation of the Effectiveness and Safety of Neoadjuvant Chemotherapy with DCF Regimen (Docetaxel, Cisplatin, 5-Flurouracil) in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients in a Tertiary Care Hospital in India: A Retrospective Study

open access: yesIndian Journal of Medical and Paediatric Oncology
Vishal Kulkarni   +8 more
doaj   +1 more source

Prospective evaluation of the Simple Fetal Medicine Foundation's first‐trimester prediction model for preeclampsia in twin pregnancies

open access: yesActa Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 9, Page 1707-1716, September 2026.
The Simple Fetal Medicine Foundation model effectively predicts preeclampsia (PE) in twin pregnancies at 11 +0–13 + 6 weeks using only maternal risk factors and mean arterial pressure. It achieves a high detection rate for early onset PE (area under the receiver operating characteristic curve 0.911 for PE <30 weeks) and provides a simple, convenient ...
Cuilian Liu   +6 more
wiley   +1 more source

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE‐O Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8552-8559, September 2026.
ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede   +10 more
wiley   +1 more source

hCG [PDF]

open access: yes, 2019
openaire   +1 more source

A Highly Powered Large Outcomes Randomised Controlled Trial Will Usually, but Not Always, Have Balanced Groups at Baseline

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8595-8601, September 2026.
ABSTRACT Objective The importance of randomised trials for discerning an intervention's effect rests on randomisation's ability to create groups with (on average) equal hazards of future outcomes. The frequency with which this does not occur in well‐designed large trials with a high event rate was studied.
Hertzel C. Gerstein   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy